This is a preprint.
Wnt7a is Required for Regeneration of Dystrophic Skeletal Muscle
- PMID: 38328077
- PMCID: PMC10849716
- DOI: 10.1101/2024.01.24.577041
Wnt7a is Required for Regeneration of Dystrophic Skeletal Muscle
Abstract
Intramuscular injection of Wnt7a has been shown to accelerate and augment skeletal muscle regeneration and to ameliorate dystrophic progression in mdx muscle, a model for Duchenne muscular dystrophy (DMD). However, loss-of-function studies to investigate the requirement for Wnt7a in muscle regeneration has not been evaluated. Here, we assessed muscle regeneration and function in wild type (WT) and mdx mice where Wnt7a was specifically deleted in muscle using a conditional Wnt7a floxed allele and a Myf5-Cre driver. We found that both WT and mdx mice with deletion of Wnt7a in muscle, exhibited marked deficiencies in muscle regeneration at 21 d following cardiotoxin (CTX) induced injury. Unlike WT, deletion of Wnt7a in mdx resulted in a marked decrease in specific force generation prior to CTX injury. However, both WT and mdx muscle lacking Wnt7a displayed decreased specific force generation following CTX injection. Notably the regeneration deficit observed in mdx mice lacking Wnt7a in muscle was rescued by a single tail vein injection of an extracellular vesicle preparation containing Wnt7a (Wnt7a-EVs). Therefore, we conclude that the regenerative capacity of muscle in mdx mice is due to the upregulation of endogenous Wnt7a following injury, and that systemic delivery of Wnt7a-EVs represents a therapeutic strategy for treating DMD.
Keywords: Duchenne Muscular Dystrophy; Extracellular Vesicles; Regeneration; Skeletal muscle; Wnt7a.
Figures
![Figure 1:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10849716/bin/nihpp-2024.01.24.577041v1-f0001.gif)
![Figure 2:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10849716/bin/nihpp-2024.01.24.577041v1-f0002.gif)
![Figure 3:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10849716/bin/nihpp-2024.01.24.577041v1-f0003.gif)
![Figure 4:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10849716/bin/nihpp-2024.01.24.577041v1-f0004.gif)
Similar articles
-
Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.Exp Physiol. 2014 Apr;99(4):675-87. doi: 10.1113/expphysiol.2013.077255. Epub 2014 Jan 17. Exp Physiol. 2014. PMID: 24443351
-
Wnt7a treatment ameliorates muscular dystrophy.Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20614-9. doi: 10.1073/pnas.1215765109. Epub 2012 Nov 26. Proc Natl Acad Sci U S A. 2012. PMID: 23185011 Free PMC article.
-
Reduction of circulating sphingosine-1-phosphate worsens mdx soleus muscle dystrophic phenotype.Exp Physiol. 2020 Nov;105(11):1895-1906. doi: 10.1113/EP088603. Epub 2020 Sep 25. Exp Physiol. 2020. PMID: 32897592
-
Co-delivery of Wnt7a and muscle stem cells using synthetic bioadhesive hydrogel enhances murine muscle regeneration and cell migration during engraftment.Acta Biomater. 2019 Aug;94:243-252. doi: 10.1016/j.actbio.2019.06.025. Epub 2019 Jun 19. Acta Biomater. 2019. PMID: 31228633 Free PMC article.
-
Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.EBioMedicine. 2017 Feb;16:150-161. doi: 10.1016/j.ebiom.2017.01.001. Epub 2017 Jan 7. EBioMedicine. 2017. PMID: 28089792 Free PMC article.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources